Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B (IN-US-0205)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Samsung Medical Center
Konkuk University Medical Center
Korea University Guro Hospital
Seoul National University Hospital
Information provided by (Responsible Party):
Young-Suk Lim, Asan Medical Center
ClinicalTrials.gov Identifier:
NCT01639066
First received: July 10, 2012
Last updated: November 23, 2013
Last verified: November 2013

July 10, 2012
November 23, 2013
September 2012
June 2014   (final data collection date for primary outcome measure)
Proportion of patients with complete virologic response [ Time Frame: at week 48 of treatment ] [ Designated as safety issue: No ]
The proportion of patients who achieve complete virologic response (serum HBV DNA concentrations below 15 IU/mL)
Same as current
Complete list of historical versions of study NCT01639066 on ClinicalTrials.gov Archive Site
  • Changes in serum HBV DNA levels [ Time Frame: at week 48 of treatment ] [ Designated as safety issue: No ]
    Changes in serum HBV DNA levels during 48 weeks of treatment
  • Proportion of patients with normal ALT [ Time Frame: at 48 weeks of treatment ] [ Designated as safety issue: No ]
  • Proportion of patients with HBe-Ag loss or seroconversion [ Time Frame: at 48 weeks of treatment ] [ Designated as safety issue: No ]
  • Proportion of patients with resistance mutations to Adefovir, Entecavir, or Tenofovir [ Time Frame: at 48 weeks of treatment ] [ Designated as safety issue: No ]
    The proportion of patients with resistance mutations to Adefovir, Entecavir, or Tenofovir at week 48
  • Proportion of patients with virologic breakthrough [ Time Frame: at 48 weeks of treatment ] [ Designated as safety issue: No ]
    Virologic breakthrough is defined as the increase in serum HBV DNA by >1 log10 (10-fold) above nadir after achieving virologic response as determined by at least 2 consecutive measurements of at least 2 weeks apart, during continued treatment
Same as current
Not Provided
Not Provided
 
Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B
A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment

With the availability of potent nucloes(t)ide analogues (NA), such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV), suppression of serum HBV DNA to undetectable levels by polymerase chain reaction (PCR) assays became achievable in most NA treatment-naïve patients. Until recently, however, many patients commenced antiviral treatment with inferior NAs prior to the availability of TDF or ETV, such as lamivudine (LAM) or adefovir (ADV) which has a low genetic barrier to resistance.

For patients who developed genotypic resistance against ADV, the efficacy of TDF monotherapy is controversial. In recent studies, TDF monotherapy produced significant suppression of HBV replication. However, only half of patients with initial ADV resistance achieved an undetectable viral load (<15 IU/ml) with 48 weeks of therapy.

On the other hand, there was a retrospective cohort study reporting that, with the combination of TDF and ETV, most of patients became HBV DNA undetectable after median 6 months of treatment. Probability of reaching complete HBV DNA suppression was not decreased in patients with ADV or ETV resistance.

Together, these observations indicate that there is a controversy about the efficacy of TDF monotherapy in patients with genotypic resistance to ADV.

Thus, in this clinical trial, the investigators will clarify whether tenofovir monotherapy is effective in inducing complete virologic response compared with tenofovir plus entecavir in CHB patients with genotypic resistance to ADV and partial virologic response to ongoing treatment.

A multi-center randomized active-controlled open-label trial

  • Patients will be randomly assigned 1:1 to receive tenofovir (300 mg/day) or tenofovir (300 mg/day) plus entecavir (1 mg/day) for 48 weeks.
  • Because over 98% of Korean patients with CHB have HBV genotype C, HBV genotype will not be determined or be regarded as a stratification factor.
  • Patients' treatment information before randomization will be retrospectively collected.(DNA change, HBeAg status, HBsAg titre, ALT, and treatment duration. etc)
  • Patients will be screened within 4 weeks before randomization to determine study eligibility.
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Chronic Viral Hepatitis B Without Delta-agent
  • Drug: Tenofovir
    Tenofovir 300mg daily Oral
    Other Name: Viread
  • Drug: Entecavir
    Entecavir 1 mg daily Oral
    Other Name: Baraclude
  • Experimental: Tenofovir plus Entecavir combination
    Tenofovir 300 mg/day orally and Entecavir 1 mg/day orally
    Interventions:
    • Drug: Tenofovir
    • Drug: Entecavir
  • Active Comparator: Tenofovir monotherapy
    Tenofovir 300 mg/day orally
    Intervention: Drug: Tenofovir
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
102
June 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria: All of below

  • Compensated liver disease (Child-Pugh class A)
  • HBsAg positive at least 6 months or more
  • HBeAg positive or negative
  • Confirmation of ADV resistance mutation at any time before screening (rtA181V or rtA181T or rtN236T)
  • Serum HBV DNA ≥ 60 IU/mL despite continued preceding oral antiviral treatment (Serum HBV DNA should be determined by the PCR assay at the local laboratory at screening for this study)
  • Patient is ambulatory.
  • Patient is willing and able to comply with the study drug regimen and all other study requirements.
  • The patient is willing and able to provide written informed consent to participate in the study.

Exclusion Criteria: Any of below

  • Patient previously received TDF for more than 1 week
  • Patient has a history of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such as suspicious foci on imaging studies. In patients with such findings, HCC should be ruled-out prior to randomizing the patient for the present study.
  • Patient has received interferon or other immunomodulatory treatment for HBV infection in the 12 months before screening for this study.
  • Patient has concomitant other chronic viral infection (HCV or HIV)
  • Patient has evidence of renal insufficiency defined as serum creatinine > 1.5 mg/dL
  • Patient has medical condition that requires concurrent use of systemic prednisolone or other immunosuppressive agent (including chemotherapeutic agent)
  • Patient is currently abusing alcohol (more than 40 g/day) or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years.
  • Patient is pregnant or breastfeeding or willing to be pregnant
  • Patient has one or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's Disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease, etc.).
  • A history of treated malignancy (other than hepatocellular carcinoma) is allowable if the patient's malignancy has been in complete remission, off chemotherapy and without additional surgical intervention, during the preceding three years.
  • Clinical signs of decompensated liver disease as indicated by any one of the following:

    1. serum bilirubin > 3 mg/dL
    2. prothrombin time > 6 seconds prolonged or INR >1.5
    3. serum albumin < 2.8 g/dL
    4. History of ascites, variceal hemorrhage, or hepatic encephalopathy
    5. Child-Pugh score ≥7
Both
20 Years to 75 Years
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT01639066
AMC2012-1208
Yes
Young-Suk Lim, Asan Medical Center
Asan Medical Center
  • Samsung Medical Center
  • Konkuk University Medical Center
  • Korea University Guro Hospital
  • Seoul National University Hospital
Principal Investigator: Young-Suk Lim, M.D., Ph.D. Asan Medical Center
Asan Medical Center
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP